Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sibutramine: current status as an anti-obesity drug and its future perspectives.

Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug; 9(12):2161-73.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.